drugset / Trial / NCT00166296
Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
Phase 2
Completed
133 enrolled
Germans Trias i Pujol Hospital
H. Lundbeck A/S · collabHoffmann-La Roche · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether the use of an antidepressant (escitalopram) can prevent depressive episodes that appear during the treatment with peg-interferon and ribavirin in patients with chronic hepatitis C.
Timeline
- Start
- 2005-03
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Escitalopram | Small molecule | 15 mg | — |